Philippe de LAVENNE is an MD by training with an MBA from HEC. With more than 35 years of experience in the pharmaceutical industry in various therapeutic areas such as cardiology, diabetes and rheumatology, he held numerous executive, strategic and commercial positions within international companies, notably within Servier & Sanofi. While Vice-president of Actelion from 2008 to 2018, he doubled the company’s sales and greatly enlarged its geographic reach. Philippe was appointed in 2018 CEO of ManRos Therapeutics and Perha Pharmaceuticals, two biotech companies undertaking preclinical and clinical development of pharmacological kinase inhibitors for the treatment of different diseases. He is now a member of the Strategic Board and supports BIOMUNEX in its strategy and development.